{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:47:13Z","timestamp":1782107233624,"version":"3.54.5"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success. Phase III interventional oncology drug trials registered at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    between 2007 and 2023 with publicly available primary endpoint results were included. Trial success was defined as the achievement of at least one primary endpoint, and tumor\u2010specific success probabilities were calculated. Multivariable logistic regression analyses were conducted to assess the association between trial success and key trial characteristics. We analyzed 824 trials (358 successful and 466 unsuccessful). Overall success probabilities were comparable between solid tumors and hematologic malignancies, although substantial heterogeneity was observed across solid tumors, with particularly low success probabilities for central nervous system tumors and pancreatic cancer. Multivariable analyses showed that biomarker\u2010based patient selection, more recently initiated trials, line of therapy, and the number of primary endpoints were associated with trial success. Trials evaluating molecularly targeted therapies and those with short\u2010term evaluable endpoints showed higher success probabilities, whereas trials evaluating chemotherapy or assessing overall or event\u2010free survival endpoints showed lower success probabilities. Phase III trial success in oncology is associated with tumor\u2010specific characteristics and development\u2010stage factors, including biomarker\u2010based patient selection and trial design. These results provide quantitative evidence to inform decision\u2010making and trial design in oncology drug development.\n                  <\/jats:p>","DOI":"10.1111\/cts.70635","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:09:25Z","timestamp":1780924165000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor\u2010Specific Success Probabilities and Factors Associated With Phase\n                    <scp>III<\/scp>\n                    Trials in Oncology Drug Development"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0706-3556","authenticated-orcid":false,"given":"Keiko","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Sciences Meiji Pharmaceutical University  Tokyo Japan"},{"name":"Genmab K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Iwase","sequence":"additional","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Sciences Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-3961","authenticated-orcid":false,"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Sciences Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y"},{"key":"e_1_2_9_4_1","first-page":"1","article-title":"Antibody\u2013Drug Conjugates in Cancer Therapy: Clinical Progress and Challenges","volume":"23","author":"Chen B.","year":"2024","journal-title":"Nature Reviews. Drug Discovery"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_9_6_1","unstructured":"Biotechnology Innovation Organization (BIO) Informa Pharma Intelligence & QLS Advisors \u201cClinical Development Success Rates and Contributing Factors 2011\u20132020 \u201d (2021)."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxx069"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2786"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.184"},{"key":"e_1_2_9_10_1","first-page":"345","article-title":"Challenges in Oncology Clinical Trials in the Era of Precision Medicine","volume":"70","author":"Hanna K. S.","year":"2020","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.65"},{"key":"e_1_2_9_12_1","first-page":"1121","article-title":"Clinical Endpoints in Oncology: A Primer","volume":"11","author":"Delgado A.","year":"2021","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0152"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-S2-19"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01007-z"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5868"},{"key":"e_1_2_9_17_1","article-title":"Evaluating the Evidence Behind Surrogate Measures in Oncology","volume":"366","author":"Gyawali B.","year":"2019","journal-title":"BMJ"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64552-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104291"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.117"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2021.100855"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0496"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114225"},{"key":"e_1_2_9_27_1","volume-title":"Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products: Guidance for Industry","author":"Food U. S.","year":"2019"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03424-3"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104515"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47080638"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.2829"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70635","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70635","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:54:08Z","timestamp":1782104048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/cts.70635"],"URL":"https:\/\/doi.org\/10.1111\/cts.70635","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70635"}}